Environmental Risk Factors for the Anti-synthetase Syndrome
NCT01276470 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 580
Last updated 2026-05-05
Summary
Background:
* Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors. Some researchers believe that people who are susceptible to autoimmune disorders develop them when the body reacts to environmental or other factors by creating white blood cells that attack the body s own tissues, which then progresses to autoimmune diseases. These immune-triggered disorders can overlap with one another to some extent, but most autoimmune diseases have certain distinct triggers.
* The autoimmune disorder myositis weakens the muscles and may cause other health problems. Environmental exposures associated with myositis include ultraviolet radiation, stressful life events and muscle overexertion, collagen implants, infections such as retroviruses and streptococci bacteria, and certain drugs and chemicals. Some individuals with myositis also produce proteins in the blood called autoantibodies that react with certain parts of the person s own cells, called synthetases, which are involved in making new proteins. A syndrome called the anti-synthetase syndrome, which includes myositis and lung disease, is associated with having the anti-synthetase autoantibodies. Researchers are interested in studying differences in environmental exposures in individuals with myositis. This study is being conducted to determine if persons with the anti-synthetase syndrome have had different environmental exposures before disease onset compared with other patients with myositis who do not have this syndrome and also compared with healthy volunteers.
Objectives:
\- To determine whether selected infectious and noninfectious environmental exposures are more common in individuals who have myositis with the anti-synthetase syndrome, compared with healthy volunteers.
Eligibility:
\- Individuals who have been diagnosed with myositis (with or without anti-synthetase autoantibodies), and healthy volunteers without autoimmune disorders.
Design:
* Participants will be screened with a full medical history and physical examination, and will provide blood, urine and house dust samples.
* Participants will complete questionnaires about their medical history and the types of exposures they have had at work, at home, and elsewhere. Participants who have myositis will also be asked about certain infections, heavy exercise or physical exertion, sun exposure, tobacco and alcohol use, and stressful events prior to being diagnosed with the disease. Healthy volunteers will be asked about the same exposures before the date of diagnosis of disease of the myositis subject to which they have been matched.
* Participants will receive a kit that contains instructions and a filter to be put onto their vacuum cleaner to collect house dust in the bedroom. This dust will be kept for possible future analyses of infectious or toxic agents based on the other results from the study.
* Individuals with myositis will have other tests as clinically indicated, including lung function tests and imaging studies.
Conditions
- Myositis
- Dermatomyositis
- Polymyositis
- Juvenile Dermatomyositis
- Juvenile Polymyositis
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Principal Investigators
-
Adam I Schiffenbauer, M.D. · National Institute of Environmental Health Sciences (NIEHS)
Eligibility
- Min Age
- 2 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-02-09
Countries
- United States
Study Locations
More Related Trials
-
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
NCT03252587 ·Status: COMPLETED ·Phase: PHASE2
-
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
NCT00582881 ·Status: COMPLETED
-
RLIP76 in Human Serum in Adults With Rheumatologic Diseases
NCT00861159 ·Status: WITHDRAWN
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
T and B Cell Responses in Autoimmune Diseases
NCT01947036 ·Status: TERMINATED
-
Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study
NCT00341198 ·Status: COMPLETED
-
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
NCT07000916 ·Status: RECRUITING
-
Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
NCT00004665 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
Immunome Project Consortium for Autoinflammatory Disorders
NCT03919110 ·Status: COMPLETED
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
Systemic Lupus Erythematosus in Gullah Health
NCT00756769 ·Status: RECRUITING
-
An Observational Study of Patients With Autoimmune Disease
NCT05842824 ·Status: NOT_YET_RECRUITING
-
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
NCT06875960 ·Status: RECRUITING ·Phase: PHASE4
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
NCT04976465 ·Status: RECRUITING ·Phase: PHASE1
-
Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases
NCT06169865 ·Status: RECRUITING
-
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216 ·Status: TERMINATED ·Phase: PHASE2
-
Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study
NCT00342095 ·Status: COMPLETED
-
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
NCT03943147 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
NCT02633163 ·Status: COMPLETED ·Phase: PHASE2
-
Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB
NCT06594861 ·Status: RECRUITING
-
Anti-infection of Low-does IL-2 in SLE
NCT02932137 ·Status: COMPLETED ·Phase: NA
-
Safety Study of AMG 557 in Subjects With Lupus Arthritis
NCT01683695 ·Status: COMPLETED ·Phase: PHASE1